Biotechnology

With new clinical data and a clear path to Phase 2 trials, Gain Therapeutics' GT-02287 offers hope for a disease-modifying therapy for Parkinson's.

Ratio Therapeutics appoints Dr. Colin Hayward as CMO, a strategic move to advance its sarcoma trial and challenge leaders in the booming radiopharmaceutical market.

A new clinical trial begins for APAC, a first-in-class drug aiming to prevent amputation and death from severe peripheral artery disease.

Positive Phase 3 results for BBP-418 offer a potential first-ever treatment for LGMD2I/R9, a progressive muscle disease with no current therapies.

Industry pioneer Lee Leichter joins EdgeOne Medical, a strategic move to master the complex, high-stakes world of combination product regulation.

A novel compound, IRX4204, shows promise in preventing triple-negative breast cancer in lab studies, offering new hope for a safe, effective preventative.

The deal with Ahngook Pharm for its GMRx2 single-pill therapy marks a key step in a global strategy validated by recent US FDA approval.

The biopharma firm's new dividend policy reflects strong 2025 results and a dual strategy of rewarding shareholders while funding M&A and expansion.

With a massive new investment, Vima Therapeutics advances a first-in-class oral drug into Phase 2, offering new hope beyond injections and surgery.

A new study validating patient-reported outcomes in HAE is set to standardize clinical trials, strengthening the case for new oral therapies like deucrictibant.

With a strong cash position and new leadership, Artiva pivots its AlloNK® cell therapy to autoimmune disease, targeting a pivotal trial for RA in 2026.

A new fellowship at the Institut Pasteur aims to revolutionize public health by training scientists in what its founder calls the '3Ms': Money, Management, and Medicine.

Eight innovators receive a major prize to pursue high-risk, radical ideas in the fight against Alzheimer’s, aiming to change the paradigm of neuroscience.

A new partnership between two Chinese biotech leaders aims to create an industrial-scale gene factory, accelerating breakthroughs in medicine and agriculture.

Following a major investment, Trialbee appoints a seasoned leader to its board, signaling a push for dominance in AI-driven clinical trial recruitment.

Biotech leader H. Martin Seidel joins Odyssey's SAB, a strategic move signaling accelerated development in the competitive autoimmune disease space.

An Alabama firm's key regulatory filing for a critical drug component could accelerate the development of cheaper cancer supportive care biosimilars.

After its Alzheimer's drug failed amidst controversy, Cassava Sciences rebrands as Filana Therapeutics, betting its future on a rare epilepsy disorder.

New analysis of Phase 1 data for NKGen Biotech’s troculeucel suggests cognitive benefits, offering a potential new weapon against neuroinflammation.

Amid fierce competition, Triangle Insights Group hires a seasoned expert to guide clients through the complex world of drug pricing and market access.